Tirzepatide: First Approval
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Tirzepatide (Mounjaro™) is a single molecule that combines dual agonism of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Native GIP and GLP-1 are incretin hormones that stimulate insulin secretion and decrease glucagon secretion. GIP also plays a role in nutrient and energy metabolism, while GLP-1 also delays gastric emptying, supresses appetite and improves satiety. Eli Lilly is developing tirzepatide for the treatment of type 2 diabetes mellitus (T2DM), obesity, cardiovascular disorders in T2DM, heart failure, non-alcoholic steatohepatitis, obstructive sleep apnoea and for reducing mortality/morbidity in obesity. In May 2022, tirzepatide received its first approval in the USA to improve glycaemic control in adults with T2DM, as an adjunct to diet and exercise. Tirzepatide is in phase III development for heart failure, obesity and cardiovascular disorders in T2DM, and in phase II development for non-alcoholic steatohepatitis. This article summarizes the milestones in the development of tirzepatide leading to this first approval for T2DM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In 2022, tirzepatide was approved by the FDA for the treatment of T2DM in the United States.135,136”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [136]
In the citing paper
“Tirzepatide is developed by Eli Lilly and has proven to provide superior blood sugar control and significant weight loss, making it particularly valuable in the treatment of T2DM.136–138”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [136]
In the citing paper
“In summary, dual and triple agonists related to GLP-1 represent significant advances in the field of diabetes treatment,167,168 demonstrating the future trend of enhancing therapeutic effects by targeting multiple biomarkers.136,169,170”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [136]
In the citing paper
“Tirzepatide (injectable, once weekly) is the first dual agonist (acting on GLP-1 and GIP receptors) approved for T2D and/or obesity management [21,35].”
Citations
Cites
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 6×
“Key clinical trials of tirzepatide sponsored by Eli Lilly and Company Drug(s) Indication Phase Status Location(s) Identifier Tirzepatide, placebo T2DM III Completed Multinational NCT03954834 (SURPASS-1) Tirzepatide, semaglutide T2DM III Completed Multinational NCT03987919 (SURPASS-2) Tirzepatide, insulin degludec T2DM…”
BackgroundMethodInfluentialTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096 · cited 5×
“Key clinical trials of tirzepatide sponsored by Eli Lilly and Company Drug(s) Indication Phase Status Location(s) Identifier Tirzepatide, placebo T2DM III Completed Multinational NCT03954834 (SURPASS-1) Tirzepatide, semaglutide T2DM III Completed Multinational NCT03987919 (SURPASS-2) Tirzepatide, insulin degludec T2DM…”
BackgroundInfluentialRosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080 · cited 5×
“Key clinical trials of tirzepatide sponsored by Eli Lilly and Company Drug(s) Indication Phase Status Location(s) Identifier Tirzepatide, placebo T2DM III Completed Multinational NCT03954834 (SURPASS-1) Tirzepatide, semaglutide T2DM III Completed Multinational NCT03987919 (SURPASS-2) Tirzepatide, insulin degludec T2DM…”
BackgroundInfluentialCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882 · cited 5×
“In a diet-induced obese mouse model, tirzepatide reduced food intake and bodyweight, with an increase in energy expenditure that might contribute to the maintenance of lower bodyweight [1].”
BackgroundInfluentialFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815 · cited 3×
“Tirzepatide reduced HbA1c in randomized, double-blind, placebo-controlled phase I (NCT03322631 [13]) and phase II studies (NCT03131687 [14]; NCT03311724 [15]) in patients with T2DM, including in Japanese patients [13].”
BackgroundInfluentialDel Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02188-7 · Cited by 684 · cited 6×
“Key clinical trials of tirzepatide sponsored by Eli Lilly and Company Drug(s) Indication Phase Status Location(s) Identifier Tirzepatide, placebo T2DM III Completed Multinational NCT03954834 (SURPASS-1) Tirzepatide, semaglutide T2DM III Completed Multinational NCT03987919 (SURPASS-2) Tirzepatide, insulin degludec T2DM…”
BackgroundInfluentialLudvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., Bray, R., & Rodríguez, Á. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01443-4 · Cited by 639 · cited 7×
“Key clinical trials of tirzepatide sponsored by Eli Lilly and Company Drug(s) Indication Phase Status Location(s) Identifier Tirzepatide, placebo T2DM III Completed Multinational NCT03954834 (SURPASS-1) Tirzepatide, semaglutide T2DM III Completed Multinational NCT03987919 (SURPASS-2) Tirzepatide, insulin degludec T2DM…”
BackgroundInfluentialDahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Rodríguez, Á. (2022) · JAMA · doi:10.1001/jama.2022.0078 · Cited by 597
Gastaldelli, A., Cusi, K., Fernández Landó, L., Bray, R., Brouwers, B., & Rodríguez, Á. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00070-5 · Cited by 513 · cited 1×
“In a substudy of SURPASS-3, tirzepatide reduced liver fat content and volumes of visceral adipose tissue and abdominal subcutaneous adipose tissue compared with insulin degludec [20].”
BackgroundHartman, M. L., Sanyal, A. J., Loomba, R., Wilson, J. M., Nikooienejad, A., Bray, R., Karanikas, C. A., Duffin, K. L., Robins, D. A., & Haupt, A. (2020) · Diabetes Care · doi:10.2337/dc19-1892 · Cited by 351 · cited 1×
“also improved levels of several biomarkers associated with cardiovascular risk [10, 11], insulin resistance [11] and nonalcoholic steatohepatitis [12].”
Background
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
GPCR drug discovery: new agents, targets and indications
Lorente, J. S., Sokolov, A. V., Ferguson, G., Schiöth, H. B., Hauser, A. S., & Gloriam, D. E. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01139-y · Cited by 251
GLP-1-based therapies for diabetes, obesity and beyond
Drucker, D. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01183-8 · Cited by 236
“155) and in 2023 for weight loss (ref.”
Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
Sinha, R., Papamargaritis, D., Sargeant, J. A., & Davies, M. J. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes22067 · Cited by 138
Structure, function and drug discovery of GPCR signaling
Cheng, L., Xia, F., Li, Z., Shen, C., Yang, Z., Hou, H., Sun, S., Feng, Y., Yong, X., Tian, X., et al. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00156-w · Cited by 152
“It mirrors the behavior of native GIP at the gastric inhibitory polypeptide receptor (GIPR) and simultaneously showcases a preference for G-protein signaling at GLP-1R [257].”
Background
Metadata
- Authors
- Syed, Y. Y.
- Affiliations
- Springer Nature (New Zealand) (NZ)
- Corresponding author
- Syed, Yahiya Y.
- ORCID
- Syed, Yahiya Y.
- Venue
- Drugs
- Published
- 2022-07
- Volume
- 82
- Issue
- 11
- Pages
- 1213-1220
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W4285087957
- Cited by
- 144
- References
- 20
- Citations by year
- 2026: 27 · 2025: 45 · 2024: 35 · 2023: 31 · 2022: 6
- FWCI
- 21.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- tirzepatide, GIP/GLP-1 dual agonist, type 2 diabetes, obesity, heart failure, nonalcoholic steatohepatitis, obstructive sleep apnea, incretins, glycemic control, drug approval, drug development
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Tirzepatide, Adult, Diabetes Mellitus, Type 2, Fatty Liver, Gastric Inhibitory Polypeptide, Heart Failure, Humans, Obesity, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tirzepatide: First Approval. https://app.cochat.ai/papers/10.1007/s40265-022-01746-8
- The paper
- Syed, Y. Y. (2022). Tirzepatide: First Approval. Drugs. https://doi.org/10.1007/s40265-022-01746-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.